邵輝博士自2020年12月起擔(dān)任本公司董事兼首席執(zhí)行官，現(xiàn)任本公司董事、副董事長(zhǎng)兼首席商務(wù)官。在此之前，邵博士于 2018 年 2 月至 2020 年 12 月?lián)我郎铮ê渡锴吧恚┑亩?、總裁及首席?zhí)行官，并自 2010 年 10 月起擔(dān)任該公司的首席財(cái)務(wù)官及全球業(yè)務(wù)負(fù)責(zé)人。此外，邵博士于 2007 年 1 月至 2010 年 10 月?lián)?Axing Pharmaceutical Company, Inc. 的高級(jí)財(cái)務(wù)副總裁及首席財(cái)務(wù)官，負(fù)責(zé)根據(jù)美國(guó)公認(rèn)會(huì)計(jì)準(zhǔn)則（GAAP）及美國(guó)證券交易委員會(huì)（SEC）的相關(guān)規(guī)則與法規(guī)編制財(cái)務(wù)報(bào)表。2005 年至 2007 年，邵博士在紐約 Kamting Street Capital Management 擔(dān)任高級(jí)生物技術(shù)分析師；2003 年至 2005 年，于紐約 Mehta Partners 擔(dān)任醫(yī)療保健分析師。在此之前，邵博士在美國(guó)羅氏制藥（Roche Pharmaceuticals）擔(dān)任首席科學(xué)家達(dá)五年之久。

邵博士于 1991 年獲中國(guó)科技大學(xué)化學(xué)學(xué)士學(xué)位，于 1996 年獲美國(guó)加州大學(xué)圣地亞哥分校生物有機(jī)化學(xué)博士學(xué)位，于 2003 年獲紐約大學(xué)斯特恩商學(xué)院金融與會(huì)計(jì)碩士學(xué)位。此外，邵博士是特許金融分析師（CFA）持證人，并持有美國(guó)注冊(cè)會(huì)計(jì)師協(xié)會(huì)（AICPA）頒發(fā)的專業(yè)資格證書。

Director, Vice Chairman of the Board and Chief Business Officer

Dr. Hui Shao has served as our director and chief executive officer since December 2020, currently acting as our director, vice chairman of the board and chief business officer. Dr. Shao served as the director, president and chief executive officer of Yisheng Biopharma from February 2018 to December 2020, and prior to that, had served as the chief financial officer and global business head of the same company since October 2010. Dr. Shao served as the senior vice president of finance and then the chief financial officer of Aoxing Pharmaceutical Company, Inc. from January 2007 to October 2010, where he was responsible for preparing financial statements in accordance with U.S. GAAP and SEC rules and regulations. From 2005 to 2007, Dr. Shao was a senior biotechnology analyst at Kamunting Street Capital Management in New York. From 2003 to 2005, Dr. Shao was a healthcare analyst at Mehta Partners in New York. Prior to that, Dr. Shao had spent five years as a principal scientist at Roche Pharmaceuticals, USA.

Dr. Shao received his bachelor’s degree in chemistry from University of Science and Technology of China in 1991, his Ph.D. degree in bioorganic chemistry from University of California, San Diego in 1996, and an M.B.A. degree in finance and accounting from Stern School of Business, New York University in 2003. Dr. Shao is a chartered financial analyst (CFA) and an AICPA holder in the State of Washington, the United States.